This morning, we announced our fourth quarter and year-end 2010 financial results. In 2010, our aggregate partner company revenue was $403 million, up 54 percent…
Posted by
Cash on our balance sheet may be growing with every well-timed exit transaction and positive momentum is driving Safeguard’s stock price upward; however, our IR…
Posted by
Earlier today in our third quarter results conference call, we announced that our aggregate partner company revenue increased 73 percent in Q3, and that for…
Posted by
Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…
Posted by
Thank you to those who were able to attend Safeguard Scientifics’ Investor Day 2010 either in person or via webcast. For those of you were…
Posted by
Just a quick reminder that Safeguard Scientifics’ Investor Day 2010 event will be held next Tuesday, October 5, from 8:00 a.m. – 11:30 a.m. at…
Posted by
On Tuesday, Oct. 5, Safeguard Scientifics will be hosting Investor Day 2010 from 8 a.m. to 11:30 a.m. EDT at The Yale Club of New…
Posted by
Last week, Safeguard Scientifics’ President and CEO Peter J. Boni sat down with Gregg Greenberg of TheStreet.com to discuss the emergence of IPO candidates from…
Posted by
On the heels of continued IPO activity, there has been a flurry of media coverage — both positive and negative — regarding the companies that…
Posted by
